Press Room

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is excited to announce ...

A partnership between the Charcot-Marie-Tooth Association (CMTA), Muscular Dystrophy Association (MDA), and other dedicated advocates has successfully passed a new law that will make flying easier for people living with Charcot-Marie-Tooth Disease (CMT). Here ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of a respected leader in science, technology, ...

What is CMT-SORD? In 2019, with Charcot-Marie-Tooth Association (CMTA) funding, researchers discovered CMT-SORD. CMTA Alliance Partner, Applied Therapeutics, then quickly identified a drug which they successfully tested in a newly CMTA-developed CMT-SORD model before rapidly advancing ...

The CMTA’s new $200K+ investment accelerates CMT1A organoid research, revolutionizing treatment evaluation for Charcot-Marie-Tooth disease (CMT) GLENOLDEN, PENNSYLVANIA, USA, February 21, 2024 — The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research ...